Yangi avlod “Magmaris” bioso‘riluvchi karkasining o‘tkir koronar sindromli bemorlarda endovaskulyar davolashda qo‘llanilishi
Annotatsiya
Maqsad. O‘tkir YUIK shakllarida (NSTEMI, STEMI) Magmaris bioso‘riluvchi karkasidan foydalanish samaradorligini baholash va uni qo‘llash asoratlarini oldini olish algoritmini ishlab chiqish.
Materiallar va usullar. O‘tkir YUIK shakllari (NSTEMI, STEMI) bilan kasallangan 64 bemorning (49 ta erkak va 15 ta ayol) klinik ma’lumotlari tahlil qilindi, ularga Magmaris bioso‘riluvchi karkasi o‘rnatilgan. Bemorlarning anamnez ma’lumotlari, umumiy klinik ko‘rsatkichlari, laboratoriya va koronaroangiografik ma’lumotlari o‘rganildi. Barcha bemorlarga endovaskulyar davolash usuli sifatida BVS-Magmaris karkasi o‘rnatilishi bilan teri orqali koronar aralashuv (TOKA)amalga oshirildi.
Natijalar. Magmaris BVS-karkasining implantatsiyasi 100% hollarda angiografik, 95,8% hollarda esa klinik muvaffaqiyat bilan tavsiflandi. Past CHQOKga ega bemorlar SYNTAX shkalasi bo‘yicha yuqori ball (p<0.001), ko‘p tomirli shikastlanishlar (p>0.05), ko‘proq koronar basseynlar jalb qilinishi (p>0.05), har bir bemorga ko‘proq SS aniqlanishi (p>0.05) va mos ravishda aterosklerotik shikastlanishning uzunligi bilan tavsiflandi. Bu teskari korrelyatsiya bilan tasdiqlandi, lekin ishonch darajasiga yetmadi, ehtimolki, bu bemorlar sonining kamligi bilan izohlanadi. Surunkali buyrak kasalligi (SBK) mavjudligi ko‘proq ko‘p tomirli va murakkab («S» turi) shikastlanishlar soni va mos ravishda ko‘proq karkas implantatsiyasi bilan bog‘liq bo‘ldi. Bunda TOKAning angiografik muvaffaqiyati 100%ni tashkil etdi, ammo klinik muvaffaqiyat SBK bo‘lmagan bemorlarga nisbatan 5,9% past bo‘ldi. 2-tur qandli diabet (QD) komorbidligi venoz arteriyalarda aterosklerotik shikastlanishlarning nisbatan uzunligi va og‘irroq («S» turi) shakllari bilan tavsiflandi. Shu bilan birga ko‘p tomirli shikastlanishlar va yurak kasalliklar soni nisbatan kamroq qayd etildi. 2-tur QD mavjudligi TOKAning angiografik muvaffaqiyatiga ta’sir qilmadi (100%), ammo klinik muvaffaqiyatni 11,1% ga pasaytirdi.
Xulosa. Mamlakatimizda Magmaris BVS-karkasidan foydalanishni baholash bo‘yicha dastlabki natijalar juda umidbaxsh bo‘ldi. Biroq ushbu yo‘nalishda yana chuqurroq tadqiqotlar olib borish zarur, xususan turli xavf omillari yoki patologik holatlarning rentgenmorfologik xususiyatlarga ta’sirini, shuningdek Magmaris polimer skaffoldining xavfsizligi va samaradorligini baholash lozim.
Mualliflar haqida
Adabiyotlar ro'yxati
EuroIntervention 2019;14:1420-1427 published online May 2018. DOI: 10.4244/EIJ-D-17-00958. https://eurointervention.pcronline.com/article/comparison-of-acute-thrombogenicity-for-magnesium- versus-stainless-steel-stents-in-a-porcine-arteriovenous-shunt-model.
Michael J Lipinski, Eduardo Acampado, Qi Cheng, Lila Adams, Sho Torii, Jiaxiang Gai, Rebecca Torguson, David G Hellinga, Michael Joner, Claus Harder, Philine Zumstein, Aloke V Finn, Frank D Kolodgie, Renu Virmani, Ron Waksman. // Comparison of acute thrombogenicity for magnesium versus stainless steel stents in a porcine arteriovenous shunt model. // PMID: 29741484 https://doi.org/10.4244/ EIJ-D-17-00958.
Johan Bennett, Quentin De Hemptinne, Keir McCutcheon. // Magmaris resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy. // Expert Rev Med Devices. 2019 Sep;16(9):757-769. https://doi.org/10.1080/17434440.2019.1649133. Epub 2019 Jul 30.
https://euat.ru/education/calculator-egfr.
Ielasi A., Cerrato E., Geraci S., Campo G., Garro N., Leoncini M., Sganzerla P., Granata F., Ruggiero R., Varbella F. Caramanno G., Grigis G., Tespili M. // Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. // Cardiology 2019;142:93–96. https://doi.org/ 10.1159/000499536
https://clinicaltrials.gov/ct2/show/NCT01168830
Michael Haude 1, Raimund Erbel, Paul Erne, Stefan Verheye, Hubertus Degen, Dirk Böse, Paul Vermeersch, Inge Wijnbergen, Neil Weissman, Francesco Prati, Ron Waksman, Jacques Koolen. // Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. // https://doi.org/10.1016/S0140-6736(12)61765-6.
Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, et al. Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE- II and BIOSOLVE-III. EuroIntervention. 2017 Jul;13(4):432–9.
https://www.sechenov.ru/upload/iblock/993/AP_Dissertatsiya_KHasanova_konvertirovan.pdf.
Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boysov S.A., Bolduyeva S.A., Garganeeva N.P., Doshitsin V.L., Karateev A.Ye., Kotovskaya Yu.V., Lila A.M., Lukyanov M.M., Morozova T.Ye., Pereverzev A.P., Petrova M.M., Pozdnyakov Yu.M., Sirov A.V., Tarasov A.V., Tkacheva O.N., Shalnova S.A. Komorbidnaya patologiya v klinicheskoy praktike. Algoritmi diagnostiki i lecheniya. Kardiovaskulyarnaya terapiya i profilaktika. 2019;18(1):5-66. https://doi.org/10.15829/1728-8800-2019- 1-5-66.
Monika Janicka, Agata Kot-Wasik, Jacek Kot, Jacek Namieśnik IsoprostanesBiomarkers of Lipid Peroxidation: Their Utility in Evaluating Oxidative Stress and Analysis Int J Mol Sci. 2010; 11(11): 4631–4659.
Rodondi N, Marques-Vidal P, et al. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol 2010; 171(5): 540-549.
Copyright (c) 2025 С.Ш. Холикулов, Н.П. Юлдошев, Aziz Eshpulatov (Автор)
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution» (««Atribut») 4.0 Butun dunyo bo'ylab.